Denali Therapeutics Inc. (DNLI) KPIs and segments

DNLINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/30

$18.74−0.15 (-0.79%)

Close on Nov 13, 2026Market cap $3.00BP/E –Yield –

KPIs & segments

Operating metrics and segments that drive Denali Therapeutics's business

Coming soon

This tab will track the numbers specific to Denali Therapeutics's business model — such as store count, revenue by banner, revenue per store and new openings — taken from filings and earnings releases.

See a number that looks wrong?